JPS58225017A - 脱ガン剤 - Google Patents

脱ガン剤

Info

Publication number
JPS58225017A
JPS58225017A JP10851782A JP10851782A JPS58225017A JP S58225017 A JPS58225017 A JP S58225017A JP 10851782 A JP10851782 A JP 10851782A JP 10851782 A JP10851782 A JP 10851782A JP S58225017 A JPS58225017 A JP S58225017A
Authority
JP
Japan
Prior art keywords
active ingredient
benzisothiazole
agent
xylene
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP10851782A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0355447B2 (https=
Inventor
Shinichi Kaiho
晋一 海宝
Fusayo Onoda
小野田　房代
Osamu Shinshi
修 進士
Koji Mizuno
水野　光司
畑　俊一
Shunichi Hata
小泉　益男
Masuo Koizumi
本多　成光
Narimitsu Honda
泰 村上
Yasushi Murakami
高垣　善男
Yoshio Takagaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP10851782A priority Critical patent/JPS58225017A/ja
Publication of JPS58225017A publication Critical patent/JPS58225017A/ja
Publication of JPH0355447B2 publication Critical patent/JPH0355447B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP10851782A 1982-06-25 1982-06-25 脱ガン剤 Granted JPS58225017A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10851782A JPS58225017A (ja) 1982-06-25 1982-06-25 脱ガン剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10851782A JPS58225017A (ja) 1982-06-25 1982-06-25 脱ガン剤

Publications (2)

Publication Number Publication Date
JPS58225017A true JPS58225017A (ja) 1983-12-27
JPH0355447B2 JPH0355447B2 (https=) 1991-08-23

Family

ID=14486795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10851782A Granted JPS58225017A (ja) 1982-06-25 1982-06-25 脱ガン剤

Country Status (1)

Country Link
JP (1) JPS58225017A (https=)

Also Published As

Publication number Publication date
JPH0355447B2 (https=) 1991-08-23

Similar Documents

Publication Publication Date Title
Hawrylowicz et al. Regulation of antigen-presentation-I. IFN-gamma induces antigen-presenting properties on B cells.
JP5681226B2 (ja) メチルフェニデート誘導体を含む治療剤
CN109294980B (zh) 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用
JP2023510291A (ja) 幹細胞の機能強化用組成物
CN110229784A (zh) 一种去除死肝细胞的分离液及利用其去除死肝细胞的方法
JPS58225017A (ja) 脱ガン剤
CN106831573A (zh) (n‑1,2,3,4‑四氢异喹啉基)‑阿魏酰胺化合物、制备方法及其应用
US20250221997A1 (en) Tyk2 inhibitor formulations and methods of making the same
JP2026506930A (ja) パーキンソン病、並びに他の一次性及び二次性パーキンソニアン障害を処置するための組合せ
CN111840278B (zh) 化合物与维生素e的组合在制备抗衰老药物或者化妆品中的用途
CN113061137B (zh) 含氮杂环衍生物或其药学上可接受的盐和用途
AU757489B2 (en) Method for inhibiting cytokine production by cells
CN102296056B (zh) 分枝杆菌噬菌体d29颗粒及其制备方法和应用
CN113476531A (zh) 组合物及其在制备保护线粒体的产品中的应用
CN116726005B (zh) 一种治疗运动损伤的药物及筛选方法和应用
Spina et al. The role of platelet activating factor in allergic inflammation
US20040102365A1 (en) Pharmaceutical composition for prevention and remedy of osteoporosis
Johnson et al. Two populations of heterozygote erythrocytes in moderate hypoxanthine guanine phosphoribosyltransferase deficiency
CN106397432B (zh) 作为jak抑制剂的一类化合物
CN119523987B (zh) 一种调控mettl3靶点的化合物在制备抗肠道病毒药物中的应用
CN115006382A (zh) 肉豆蔻酸在制备用于抗老年性骨质疏松药物中的应用
CN112245433B (zh) 依克多因类物质在制备防治缺血性脑卒中药物中的应用
Featherston CONVULSIONS FOLLOWING USE OF ASTEROL® DIHYDROCHLORIDE: REPORT OF A CASE
CN108272789B (zh) Ramosissimin在制备治疗类风湿关节炎药物的应用
TW202529769A (zh) Ｔｙｋ２抑制劑及其用途